Orion Bioscience Inc is a biotech company focused on development of immune therapeutics to intercept and prevent the progression of autoimmune diseases using proprietary polymer-peptide conjugates designated 'Soluble Antigen Arrays' starting with Type-1 diabetes and neuromyelitis optica. Affecting 50M Americans annually, autoimmune disease develops when there is a breakdown in peripheral tolerance in the body - a condition that allows autoreactive immune cells to enter the circulatory system and attack healthy tissue. Pre-disease markers exist in the patient before diagnosis. Involving collaboration with work funded by JDRF, Orion BioScience is addressing treatment of the patient in that âprediseaseâ stage. a drug platform designed to restore immune tolerance as a way to cure autoimmune diseases. The company's drug platform organizes around therapeutic modalities designed to ameliorate the devastating effects of autoimmune diseases with enabling patient access to novel therapies for the treatment of severe eye diseases often associated to their conditi